首页 > 最新文献

Journal of negative results in biomedicine最新文献

英文 中文
Unexpected combined effects of NADH dehydrogenase subunit-2 237 Leu/Met polymorphism and green tea consumption on renal function in male Japanese health check-up examinees: a cross-sectional study. NADH脱氢酶亚基-2 237 Leu/Met多态性和绿茶摄入对日本男性健康体检者肾功能的意外联合影响:一项横断面研究
Pub Date : 2013-11-20 DOI: 10.1186/1477-5751-12-17
Akatsuki Kokaze, Mamoru Ishikawa, Naomi Matsunaga, Kanae Karita, Masao Yoshida, Tadahiro Ohtsu, Hirotaka Ochiai, Takako Shirasawa, Hinako Nanri, Hiromi Hoshino, Yutaka Takashima

Background: NADH dehydrogenase subunit-2 237 leucine/methionine (ND2-237 Leu/Met) polymorphism is associated with longevity in Japanese. A previous study has shown that ND2-237 Leu/Met polymorphism modulates the effects of green tea consumption on risk of hypertension. For men with ND2-237Leu, habitual green tea consumption may reduce the risk of hypertension. Moreover, there is a combined effect of ND2-237 Leu/Met polymorphism and alcohol consumption on risk of mildly decreased estimated glomerular filtration rate (eGFR) (<90 ml/min/1.73 m2). Several beneficial effects of green tea on the kidney have been reported. The objective of this study was to investigate whether ND2-237 Leu/Met polymorphism modifies the effects of green tea consumption on risk of mildly decreased eGFR in male Japanese health check-up examinees.

Results: For ND2-237Leu genotypic men, after adjustment for confounding factors, green tea consumption may increase the risk of mildly decreased eGFR (P for trend = 0.016). The adjusted odds ratio (OR) for mildly decreased eGFR was significantly higher in subjects with ND2-237Leu who consume ≥6 cups of green tea per day than those who consume ≤1 cup of green tea per day (adjusted OR = 5.647, 95% confidence interval: 1.528-20.88, P = 0.009). On the other hand, for ND2-237Met genotypic men, green tea consumption does not appear to determine the risk of mildly decreased eGFR.

Conclusion: The present results suggest that ND2-237 Leu/Met polymorphism unexpectedly modifies the effects of green tea consumption on eGFR and the risk of mildly decreased eGFR in male Japanese subjects.

背景:NADH脱氢酶亚基-2 237亮氨酸/蛋氨酸(ND2-237亮氨酸/蛋氨酸)多态性与日本人的寿命有关。先前的一项研究表明,ND2-237亮氨酸/蛋氨酸多态性调节了绿茶摄入对高血压风险的影响。对于ND2-237Leu的男性,经常饮用绿茶可能会降低患高血压的风险。此外,ND2-237Leu /Met多态性和饮酒对估计肾小球滤过率(eGFR)轻度降低的风险有联合影响(结果:对于ND2-237Leu基因型男性,在调整混杂因素后,饮用绿茶可能增加轻度降低的风险eGFR (P趋势= 0.016)。在ND2-237Leu受试者中,每天饮用≥6杯绿茶的eGFR轻度降低的校正比值比(OR)显著高于每天饮用≤1杯绿茶的受试者(OR = 5.647, 95%可信区间:1.528-20.88,P = 0.009)。另一方面,对于ND2-237Met基因型男性,绿茶摄入量似乎并不能决定eGFR轻度降低的风险。结论:ND2-237 Leu/Met多态性出乎意料地改变了绿茶摄入对日本男性eGFR的影响和轻度降低eGFR的风险。
{"title":"Unexpected combined effects of NADH dehydrogenase subunit-2 237 Leu/Met polymorphism and green tea consumption on renal function in male Japanese health check-up examinees: a cross-sectional study.","authors":"Akatsuki Kokaze,&nbsp;Mamoru Ishikawa,&nbsp;Naomi Matsunaga,&nbsp;Kanae Karita,&nbsp;Masao Yoshida,&nbsp;Tadahiro Ohtsu,&nbsp;Hirotaka Ochiai,&nbsp;Takako Shirasawa,&nbsp;Hinako Nanri,&nbsp;Hiromi Hoshino,&nbsp;Yutaka Takashima","doi":"10.1186/1477-5751-12-17","DOIUrl":"https://doi.org/10.1186/1477-5751-12-17","url":null,"abstract":"<p><strong>Background: </strong>NADH dehydrogenase subunit-2 237 leucine/methionine (ND2-237 Leu/Met) polymorphism is associated with longevity in Japanese. A previous study has shown that ND2-237 Leu/Met polymorphism modulates the effects of green tea consumption on risk of hypertension. For men with ND2-237Leu, habitual green tea consumption may reduce the risk of hypertension. Moreover, there is a combined effect of ND2-237 Leu/Met polymorphism and alcohol consumption on risk of mildly decreased estimated glomerular filtration rate (eGFR) (<90 ml/min/1.73 m2). Several beneficial effects of green tea on the kidney have been reported. The objective of this study was to investigate whether ND2-237 Leu/Met polymorphism modifies the effects of green tea consumption on risk of mildly decreased eGFR in male Japanese health check-up examinees.</p><p><strong>Results: </strong>For ND2-237Leu genotypic men, after adjustment for confounding factors, green tea consumption may increase the risk of mildly decreased eGFR (P for trend = 0.016). The adjusted odds ratio (OR) for mildly decreased eGFR was significantly higher in subjects with ND2-237Leu who consume ≥6 cups of green tea per day than those who consume ≤1 cup of green tea per day (adjusted OR = 5.647, 95% confidence interval: 1.528-20.88, P = 0.009). On the other hand, for ND2-237Met genotypic men, green tea consumption does not appear to determine the risk of mildly decreased eGFR.</p><p><strong>Conclusion: </strong>The present results suggest that ND2-237 Leu/Met polymorphism unexpectedly modifies the effects of green tea consumption on eGFR and the risk of mildly decreased eGFR in male Japanese subjects.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31880817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The methodological quality of three foundational law enforcement Drug Influence Evaluation validation studies. 三项基础性执法毒品影响评估验证研究的方法质量。
Pub Date : 2013-11-04 DOI: 10.1186/1477-5751-12-16
Greg Kane

Background: A Drug Influence Evaluation (DIE) is a formal assessment of an impaired driving suspect, performed by a trained law enforcement officer who uses circumstantial facts, questioning, searching, and a physical exam to form an unstandardized opinion as to whether a suspect's driving was impaired by drugs. This paper first identifies the scientific studies commonly cited in American criminal trials as evidence of DIE accuracy, and second, uses the QUADAS tool to investigate whether the methodologies used by these studies allow them to correctly quantify the diagnostic accuracy of the DIEs currently administered by US law enforcement.

Results: Three studies were selected for analysis. For each study, the QUADAS tool identified biases that distorted reported accuracies. The studies were subject to spectrum bias, selection bias, misclassification bias, verification bias, differential verification bias, incorporation bias, and review bias. The studies quantified DIE performance with prevalence-dependent accuracy statistics that are internally but not externally valid.

Conclusion: The accuracies reported by these studies do not quantify the accuracy of the DIE process now used by US law enforcement. These studies do not validate current DIE practice.

背景:药物影响评估(DIE)是由一名训练有素的执法人员对驾驶能力受损的嫌疑人进行的正式评估,执法人员通过间接事实、询问、搜查和身体检查,对嫌疑人的驾驶是否受到药物影响形成非标准化的意见。本文首先确定了在美国刑事审判中常被引用作为DIE准确性证据的科学研究,其次使用QUADAS工具调查这些研究使用的方法是否能够正确量化美国执法部门目前使用的DIE的诊断准确性:我们选择了三项研究进行分析。对于每项研究,QUADAS 工具都发现了歪曲报告准确性的偏差。这些研究存在频谱偏差、选择偏差、误分类偏差、验证偏差、差异验证偏差、纳入偏差和审查偏差。这些研究通过依赖于流行率的准确性统计来量化 DIE 的性能,这些统计具有内部有效性,但不具有外部有效性:结论:这些研究报告的准确性并不能量化美国执法部门目前使用的 DIE 流程的准确性。这些研究并未验证当前的 DIE 实践。
{"title":"The methodological quality of three foundational law enforcement Drug Influence Evaluation validation studies.","authors":"Greg Kane","doi":"10.1186/1477-5751-12-16","DOIUrl":"10.1186/1477-5751-12-16","url":null,"abstract":"<p><strong>Background: </strong>A Drug Influence Evaluation (DIE) is a formal assessment of an impaired driving suspect, performed by a trained law enforcement officer who uses circumstantial facts, questioning, searching, and a physical exam to form an unstandardized opinion as to whether a suspect's driving was impaired by drugs. This paper first identifies the scientific studies commonly cited in American criminal trials as evidence of DIE accuracy, and second, uses the QUADAS tool to investigate whether the methodologies used by these studies allow them to correctly quantify the diagnostic accuracy of the DIEs currently administered by US law enforcement.</p><p><strong>Results: </strong>Three studies were selected for analysis. For each study, the QUADAS tool identified biases that distorted reported accuracies. The studies were subject to spectrum bias, selection bias, misclassification bias, verification bias, differential verification bias, incorporation bias, and review bias. The studies quantified DIE performance with prevalence-dependent accuracy statistics that are internally but not externally valid.</p><p><strong>Conclusion: </strong>The accuracies reported by these studies do not quantify the accuracy of the DIE process now used by US law enforcement. These studies do not validate current DIE practice.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31831258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depression treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with chronic physical conditions. 患有慢性身体疾病的老年医疗保险受益人的抑郁症治疗和短期医疗保健支出。
Pub Date : 2013-10-22 DOI: 10.1186/1477-5751-12-15
Chan Shen, Neel Shah, Patricia A Findley, Usha Sambamoorthi

Background: Research on the impact of depression treatment on expenditures is nascent and shows results that vary from negative associations with healthcare expenditures to increased expenditures. However many of these studies did not include psychotherapy as part of the depression treatment. None of these studies included "no treatment" as a comparison group. In addition, no study has included a broad group of chronic physical conditions in studying depression treatment expenditures.

Objective: We determined the association between depression treatment and short-term healthcare expenditures using a nationally representative sample of Medicare beneficiaries with chronic physical conditions and depression.

Method: In this retrospective cohort study, we examined the association between depression treatment in the baseline year and healthcare expenditures in the following year using data from 2000 through 2005 of the Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of Medicare beneficiaries. Using the rotating panel design of MCBS, we derived five two-year cohorts: 2000-2001, 2001-2002, 2002-2003, 2003-2004, and 2004-2005. The study sample included 1,055 elderly Medicare beneficiaries aged 65 or over. We compared healthcare expenditures of no depression treatment group with depression treatment groups using t-tests. Linear regressions of log-transformed dollars were used to assess the relationship between depression treatment and healthcare expenditures after controlling for demographic, socio-economic, health status, lifestyle risk factors, year of observation and baseline expenditures.

Results: Compared to no depression treatment ($16,795), the average total expenditures were higher for those who used antidepressants only ($17,425) and those who used psychotherapy with or without antidepressants ($19,733). After controlling for the independent variables, antidepressant use and psychotherapy with or without antidepressants were associated with 20.2% (95% CI: 14.1-26.7%) and 29.4% (95% CI: 18.8-41.0%) increase in total expenditures, respectively. We observed that depression treatment was positively associated with inpatient, medical provider and prescription drug expenditures.

Conclusion: Among the elderly Medicare beneficiaries with chronic physical conditions, depression treatment was associated with greater short-term healthcare expenditures. Future research needs to replicate these findings and also examine whether depression treatment reduces expenditures over a longer period of time.

背景:关于抑郁症治疗对支出影响的研究是新生的,其结果从与医疗支出的负相关到与支出的增加不等。然而,许多研究并没有将心理治疗作为抑郁症治疗的一部分。这些研究都没有将“不治疗”作为对照组。此外,没有一项研究在研究抑郁症治疗费用时纳入了广泛的慢性身体状况。目的:我们确定抑郁症治疗与短期医疗保健支出之间的关系,使用具有全国代表性的慢性身体状况和抑郁症的医疗保险受益人样本。方法:在这项回顾性队列研究中,我们使用2000 - 2005年医疗保险受益人调查(MCBS)的数据,研究了基准年的抑郁症治疗与次年医疗保健支出之间的关系,MCBS是一项全国代表性的医疗保险受益人调查。使用MCBS的轮换面板设计,我们导出了5个2年期队列:2000-2001年、2001-2002年、2002-2003年、2003-2004年和2004-2005年。研究样本包括1055名65岁或以上的老年医疗保险受益人。我们用t检验比较了未治疗抑郁症组和治疗抑郁症组的医疗费用。在控制了人口统计学、社会经济、健康状况、生活方式风险因素、观察年份和基线支出后,采用对数转换美元的线性回归来评估抑郁症治疗与医疗保健支出之间的关系。结果:与没有抑郁症治疗(16,795美元)相比,仅使用抗抑郁药物的患者(17,425美元)和使用或不使用抗抑郁药物的心理治疗患者(19,733美元)的平均总支出更高。在控制了自变量后,抗抑郁药的使用和有或没有抗抑郁药的心理治疗分别与总支出增加20.2% (95% CI: 14.1-26.7%)和29.4% (95% CI: 18.8-41.0%)相关。我们观察到抑郁症治疗与住院病人、医疗提供者和处方药支出呈正相关。结论:在患有慢性身体疾病的老年医疗保险受益人中,抑郁症治疗与较大的短期医疗保健支出相关。未来的研究需要重复这些发现,并检查抑郁症治疗是否能在较长一段时间内减少支出。
{"title":"Depression treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with chronic physical conditions.","authors":"Chan Shen,&nbsp;Neel Shah,&nbsp;Patricia A Findley,&nbsp;Usha Sambamoorthi","doi":"10.1186/1477-5751-12-15","DOIUrl":"https://doi.org/10.1186/1477-5751-12-15","url":null,"abstract":"<p><strong>Background: </strong>Research on the impact of depression treatment on expenditures is nascent and shows results that vary from negative associations with healthcare expenditures to increased expenditures. However many of these studies did not include psychotherapy as part of the depression treatment. None of these studies included \"no treatment\" as a comparison group. In addition, no study has included a broad group of chronic physical conditions in studying depression treatment expenditures.</p><p><strong>Objective: </strong>We determined the association between depression treatment and short-term healthcare expenditures using a nationally representative sample of Medicare beneficiaries with chronic physical conditions and depression.</p><p><strong>Method: </strong>In this retrospective cohort study, we examined the association between depression treatment in the baseline year and healthcare expenditures in the following year using data from 2000 through 2005 of the Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of Medicare beneficiaries. Using the rotating panel design of MCBS, we derived five two-year cohorts: 2000-2001, 2001-2002, 2002-2003, 2003-2004, and 2004-2005. The study sample included 1,055 elderly Medicare beneficiaries aged 65 or over. We compared healthcare expenditures of no depression treatment group with depression treatment groups using t-tests. Linear regressions of log-transformed dollars were used to assess the relationship between depression treatment and healthcare expenditures after controlling for demographic, socio-economic, health status, lifestyle risk factors, year of observation and baseline expenditures.</p><p><strong>Results: </strong>Compared to no depression treatment ($16,795), the average total expenditures were higher for those who used antidepressants only ($17,425) and those who used psychotherapy with or without antidepressants ($19,733). After controlling for the independent variables, antidepressant use and psychotherapy with or without antidepressants were associated with 20.2% (95% CI: 14.1-26.7%) and 29.4% (95% CI: 18.8-41.0%) increase in total expenditures, respectively. We observed that depression treatment was positively associated with inpatient, medical provider and prescription drug expenditures.</p><p><strong>Conclusion: </strong>Among the elderly Medicare beneficiaries with chronic physical conditions, depression treatment was associated with greater short-term healthcare expenditures. Future research needs to replicate these findings and also examine whether depression treatment reduces expenditures over a longer period of time.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40257921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Air ions and respiratory function outcomes: a comprehensive review. 空气离子与呼吸功能预后的综合综述。
Pub Date : 2013-09-09 DOI: 10.1186/1477-5751-12-14
Dominik D Alexander, William H Bailey, Vanessa Perez, Meghan E Mitchell, Steave Su

Background: From a mechanistic or physical perspective there is no basis to suspect that electric charges on clusters of air molecules (air ions) would have beneficial or deleterious effects on respiratory function. Yet, there is a large lay and scientific literature spanning 80 years that asserts exposure to air ions affects the respiratory system and has other biological effects.

Aims: This review evaluates the scientific evidence in published human experimental studies regarding the effects of exposure to air ions on respiratory performance and symptoms.

Methods: We identified 23 studies (published 1933-1993) that met our inclusion criteria. Relevant data pertaining to study population characteristics, study design, experimental methods, statistical techniques, and study results were assessed. Where relevant, random effects meta-analysis models were utilized to quantify similar exposure and outcome groupings.

Results: The included studies examined the therapeutic benefits of exposure to negative air ions on respiratory outcomes, such as ventilatory function and asthmatic symptoms. Study specific sample sizes ranged between 7 and 23, and studies varied considerably by subject characteristics (e.g., infants with asthma, adults with emphysema), experimental method, outcomes measured (e.g., subjective symptoms, sensitivity, clinical pulmonary function), analytical design, and statistical reporting.

Conclusions: Despite numerous experimental and analytical differences across studies, the literature does not clearly support a beneficial role in exposure to negative air ions and respiratory function or asthmatic symptom alleviation. Further, collectively, the human experimental studies do not indicate a significant detrimental effect of exposure to positive air ions on respiratory measures. Exposure to negative or positive air ions does not appear to play an appreciable role in respiratory function.

背景:从机械或物理的角度来看,没有理由怀疑空气分子簇(空气离子)上的电荷对呼吸功能有有益或有害的影响。然而,跨越80年的大量非专业和科学文献断言,暴露于空气离子会影响呼吸系统并产生其他生物效应。目的:本综述评估了已发表的人体实验研究中关于暴露于空气离子对呼吸功能和症状影响的科学证据。方法:我们确定了23项研究(发表于1933-1993年)符合我们的纳入标准。评估有关研究人群特征、研究设计、实验方法、统计技术和研究结果的相关数据。在相关的情况下,使用随机效应荟萃分析模型来量化相似的暴露和结果分组。结果:纳入的研究检查了暴露于负空气离子对呼吸结果(如通气功能和哮喘症状)的治疗益处。研究的具体样本量在7到23个之间,研究因受试者特征(如患有哮喘的婴儿、患有肺气肿的成人)、实验方法、测量结果(如主观症状、敏感性、临床肺功能)、分析设计和统计报告而有很大差异。结论:尽管各研究之间存在大量实验和分析差异,但文献并未明确支持暴露于负空气离子对呼吸功能或哮喘症状缓解的有益作用。此外,总的来说,人体实验研究并未表明暴露于正空气离子对呼吸措施有显著的有害影响。暴露于负离子或正离子空气中似乎对呼吸功能没有明显影响。
{"title":"Air ions and respiratory function outcomes: a comprehensive review.","authors":"Dominik D Alexander,&nbsp;William H Bailey,&nbsp;Vanessa Perez,&nbsp;Meghan E Mitchell,&nbsp;Steave Su","doi":"10.1186/1477-5751-12-14","DOIUrl":"https://doi.org/10.1186/1477-5751-12-14","url":null,"abstract":"<p><strong>Background: </strong>From a mechanistic or physical perspective there is no basis to suspect that electric charges on clusters of air molecules (air ions) would have beneficial or deleterious effects on respiratory function. Yet, there is a large lay and scientific literature spanning 80 years that asserts exposure to air ions affects the respiratory system and has other biological effects.</p><p><strong>Aims: </strong>This review evaluates the scientific evidence in published human experimental studies regarding the effects of exposure to air ions on respiratory performance and symptoms.</p><p><strong>Methods: </strong>We identified 23 studies (published 1933-1993) that met our inclusion criteria. Relevant data pertaining to study population characteristics, study design, experimental methods, statistical techniques, and study results were assessed. Where relevant, random effects meta-analysis models were utilized to quantify similar exposure and outcome groupings.</p><p><strong>Results: </strong>The included studies examined the therapeutic benefits of exposure to negative air ions on respiratory outcomes, such as ventilatory function and asthmatic symptoms. Study specific sample sizes ranged between 7 and 23, and studies varied considerably by subject characteristics (e.g., infants with asthma, adults with emphysema), experimental method, outcomes measured (e.g., subjective symptoms, sensitivity, clinical pulmonary function), analytical design, and statistical reporting.</p><p><strong>Conclusions: </strong>Despite numerous experimental and analytical differences across studies, the literature does not clearly support a beneficial role in exposure to negative air ions and respiratory function or asthmatic symptom alleviation. Further, collectively, the human experimental studies do not indicate a significant detrimental effect of exposure to positive air ions on respiratory measures. Exposure to negative or positive air ions does not appear to play an appreciable role in respiratory function.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31717656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Biological constraints limit the use of rapamycin-inducible FKBP12-Inp54p for depleting PIP2 in dorsal root ganglia neurons. 生物学限制限制了使用雷帕霉素诱导的FKBP12-Inp54p来消耗背根神经节神经元中的PIP2。
Pub Date : 2013-09-08 DOI: 10.1186/1477-5751-12-13
Jaeda C Coutinho-Budd, Samuel B Snider, Brendan J Fitzpatrick, Joseph E Rittiner, Mark J Zylka

Background: Rapamycin-induced translocation systems can be used to manipulate biological processes with precise temporal control. These systems are based on rapamycin-induced dimerization of FK506 Binding Protein 12 (FKBP12) with the FKBP Rapamycin Binding (FRB) domain of mammalian target of rapamycin (mTOR). Here, we sought to adapt a rapamycin-inducible phosphatidylinositol 4,5-bisphosphate (PIP2)-specific phosphatase (Inp54p) system to deplete PIP2 in nociceptive dorsal root ganglia (DRG) neurons.

Results: We genetically targeted membrane-tethered CFP-FRBPLF (a destabilized FRB mutant) to the ubiquitously expressed Rosa26 locus, generating a Rosa26-FRBPLF knockin mouse. In a second knockin mouse line, we targeted Venus-FKBP12-Inp54p to the Calcitonin gene-related peptide-alpha (CGRPα) locus. We hypothesized that after intercrossing these mice, rapamycin treatment would induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in CGRP+ DRG neurons. In control experiments with cell lines, rapamycin induced translocation of Venus-FKBP12-Inp54p to the plasma membrane, and subsequent depletion of PIP2, as measured with a PIP2 biosensor. However, rapamycin did not induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in FRBPLF-expressing DRG neurons (in vitro or in vivo). Moreover, rapamycin treatment did not alter PIP2-dependent thermosensation in vivo. Instead, rapamycin treatment stabilized FRBPLF in cultured DRG neurons, suggesting that rapamycin promoted dimerization of FRBPLF with endogenous FKBP12.

Conclusions: Taken together, our data indicate that these knockin mice cannot be used to inducibly deplete PIP2 in DRG neurons. Moreover, our data suggest that high levels of endogenous FKBP12 could compete for binding to FRBPLF, hence limiting the use of rapamycin-inducible systems to cells with low levels of endogenous FKBP12.

背景:雷帕霉素诱导的易位系统可用于操纵具有精确时间控制的生物过程。这些系统是基于雷帕霉素诱导的FK506结合蛋白12 (FKBP12)与哺乳动物雷帕霉素靶点(mTOR)的FKBP雷帕霉素结合(FRB)结构域的二聚化。在这里,我们试图采用雷帕霉素诱导的磷脂酰肌醇4,5-二磷酸(PIP2)特异性磷酸酶(Inp54p)系统来消耗伤害性背根神经节(DRG)神经元中的PIP2。结果:我们将膜系CFP-FRBPLF(一种不稳定的FRB突变体)基因靶向到普遍表达的Rosa26位点,产生了Rosa26- frbplf敲入小鼠。在第二个敲入小鼠系中,我们将Venus-FKBP12-Inp54p靶向降钙素基因相关肽α (CGRPα)位点。我们假设,在这些小鼠交叉后,雷帕霉素处理会诱导Venus-FKBP12-Inp54p易位到CGRP+ DRG神经元的质膜上。在细胞系对照实验中,用PIP2生物传感器测量,雷帕霉素诱导Venus-FKBP12-Inp54p易位至质膜,随后PIP2耗损。然而,在体外或体内,雷帕霉素并未诱导表达frbplf的DRG神经元中Venus-FKBP12-Inp54p易位到质膜上。此外,雷帕霉素治疗并未改变体内pip2依赖性热感觉。相反,雷帕霉素治疗稳定了培养DRG神经元中的FRBPLF,这表明雷帕霉素促进了FRBPLF与内源性FKBP12的二聚化。综上所述,我们的数据表明,这些敲入小鼠不能用于诱导DRG神经元中PIP2的消耗。此外,我们的数据表明,高水平的内源性FKBP12可能会竞争与FRBPLF的结合,因此限制了雷帕霉素诱导系统在低水平内源性FKBP12细胞中的应用。
{"title":"Biological constraints limit the use of rapamycin-inducible FKBP12-Inp54p for depleting PIP2 in dorsal root ganglia neurons.","authors":"Jaeda C Coutinho-Budd,&nbsp;Samuel B Snider,&nbsp;Brendan J Fitzpatrick,&nbsp;Joseph E Rittiner,&nbsp;Mark J Zylka","doi":"10.1186/1477-5751-12-13","DOIUrl":"https://doi.org/10.1186/1477-5751-12-13","url":null,"abstract":"<p><strong>Background: </strong>Rapamycin-induced translocation systems can be used to manipulate biological processes with precise temporal control. These systems are based on rapamycin-induced dimerization of FK506 Binding Protein 12 (FKBP12) with the FKBP Rapamycin Binding (FRB) domain of mammalian target of rapamycin (mTOR). Here, we sought to adapt a rapamycin-inducible phosphatidylinositol 4,5-bisphosphate (PIP2)-specific phosphatase (Inp54p) system to deplete PIP2 in nociceptive dorsal root ganglia (DRG) neurons.</p><p><strong>Results: </strong>We genetically targeted membrane-tethered CFP-FRBPLF (a destabilized FRB mutant) to the ubiquitously expressed Rosa26 locus, generating a Rosa26-FRBPLF knockin mouse. In a second knockin mouse line, we targeted Venus-FKBP12-Inp54p to the Calcitonin gene-related peptide-alpha (CGRPα) locus. We hypothesized that after intercrossing these mice, rapamycin treatment would induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in CGRP+ DRG neurons. In control experiments with cell lines, rapamycin induced translocation of Venus-FKBP12-Inp54p to the plasma membrane, and subsequent depletion of PIP2, as measured with a PIP2 biosensor. However, rapamycin did not induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in FRBPLF-expressing DRG neurons (in vitro or in vivo). Moreover, rapamycin treatment did not alter PIP2-dependent thermosensation in vivo. Instead, rapamycin treatment stabilized FRBPLF in cultured DRG neurons, suggesting that rapamycin promoted dimerization of FRBPLF with endogenous FKBP12.</p><p><strong>Conclusions: </strong>Taken together, our data indicate that these knockin mice cannot be used to inducibly deplete PIP2 in DRG neurons. Moreover, our data suggest that high levels of endogenous FKBP12 could compete for binding to FRBPLF, hence limiting the use of rapamycin-inducible systems to cells with low levels of endogenous FKBP12.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31712263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Serotonin: a novel bone mass controller may have implications for alveolar bone. 血清素:一种新的骨量控制器可能对牙槽骨有影响。
Pub Date : 2013-08-21 DOI: 10.1186/1477-5751-12-12
Carlo Galli, Guido Macaluso, Giovanni Passeri

As recent studies highlight the importance of alternative mechanisms in the control of bone turnover, new therapeutic approaches can be envisaged for bone diseases and periodontitis-induced bone loss. Recently, it has been shown that Fluoxetine and Venlafaxine, serotonin re-uptake inhibitors commonly used as antidepressants, can positively or negatively affect bone loss in rat models of induced periodontitis. Serotonin is a neurotransmitter that can be found within specific nuclei of the central nervous system, but can also be produced in the gut and be sequestered inside platelet granules. Although it is known to be mainly involved in the control of mood, sleep, and intestinal physiology, recent evidence has pointed at far reaching effects on bone metabolism, as a mediator of the effects of Lrp5, a membrane receptor commonly associated with Wnt canonical signaling and osteoblast differentiation. Deletion of Lrp5 in mice lead to increased expression of Tryptophan Hydroxylase 1, the gut isoform of the enzyme required for serotonin synthesis, thus increasing serum levels of serotonin. Serotonin, in turn, could bind to HTR1B receptors on osteoblasts and stop their proliferation by activating PKA and CREB.Although different groups have reported controversial results on the existence of an Lrp5-serotonin axis and the action of serotonin in bone remodeling, there is convincing evidence that serotonin modulators such as SSRIs can affect bone turnover. Consequently, the effects of this drug family on periodontal physiology should be thoroughly explored.

由于最近的研究强调了控制骨转换的其他机制的重要性,可以设想新的治疗方法来治疗骨病和牙周炎引起的骨质流失。最近有研究表明,氟西汀和文拉法辛这两种血清素再摄取抑制剂通常被用作抗抑郁药,对大鼠牙周炎模型的骨质流失有积极或消极的影响。血清素是一种神经递质,可以在中枢神经系统的特定细胞核中发现,但也可以在肠道中产生并被隔离在血小板颗粒中。虽然已知它主要参与情绪、睡眠和肠道生理的控制,但最近的证据表明,作为Lrp5(一种通常与Wnt规范信号传导和成骨细胞分化相关的膜受体)作用的介质,它对骨代谢有深远的影响。在小鼠中,Lrp5的缺失导致色氨酸羟化酶1的表达增加,色氨酸羟化酶1是合成血清素所需的酶的肠道异构体,从而增加血清血清素水平。反过来,血清素可以与成骨细胞上的HTR1B受体结合,并通过激活PKA和CREB来阻止它们的增殖。尽管不同的研究小组对lrp5 - 5-羟色胺轴的存在和5-羟色胺在骨重塑中的作用的研究结果存在争议,但有令人信服的证据表明,5-羟色胺调节剂如SSRIs可以影响骨转换。因此,该药物家族对牙周生理的影响应深入探讨。
{"title":"Serotonin: a novel bone mass controller may have implications for alveolar bone.","authors":"Carlo Galli,&nbsp;Guido Macaluso,&nbsp;Giovanni Passeri","doi":"10.1186/1477-5751-12-12","DOIUrl":"https://doi.org/10.1186/1477-5751-12-12","url":null,"abstract":"<p><p>As recent studies highlight the importance of alternative mechanisms in the control of bone turnover, new therapeutic approaches can be envisaged for bone diseases and periodontitis-induced bone loss. Recently, it has been shown that Fluoxetine and Venlafaxine, serotonin re-uptake inhibitors commonly used as antidepressants, can positively or negatively affect bone loss in rat models of induced periodontitis. Serotonin is a neurotransmitter that can be found within specific nuclei of the central nervous system, but can also be produced in the gut and be sequestered inside platelet granules. Although it is known to be mainly involved in the control of mood, sleep, and intestinal physiology, recent evidence has pointed at far reaching effects on bone metabolism, as a mediator of the effects of Lrp5, a membrane receptor commonly associated with Wnt canonical signaling and osteoblast differentiation. Deletion of Lrp5 in mice lead to increased expression of Tryptophan Hydroxylase 1, the gut isoform of the enzyme required for serotonin synthesis, thus increasing serum levels of serotonin. Serotonin, in turn, could bind to HTR1B receptors on osteoblasts and stop their proliferation by activating PKA and CREB.Although different groups have reported controversial results on the existence of an Lrp5-serotonin axis and the action of serotonin in bone remodeling, there is convincing evidence that serotonin modulators such as SSRIs can affect bone turnover. Consequently, the effects of this drug family on periodontal physiology should be thoroughly explored. </p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31673617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Clinical significance and diagnostic usefulness of serologic markers for improvement of outcome of tonsillectomy in adults with chronic tonsillitis. 成人慢性扁桃体炎扁桃体切除术后血清学指标改善预后的临床意义及诊断价值。
Pub Date : 2013-07-01 DOI: 10.1186/1477-5751-12-11
Silvia Bohne, Robert Siggel, Svea Sachse, Michael Kiehntopf, Michael Bauer, Eberhard Straube, Orlando Guntinas-Lichius

Background: The aim of the present study was to explore serological biomarkers which predict the outcome of tonsillectomy for chronic tonsillitis.

Methods: A case study in a University ENT department of 24 adult patients with chronic tonsillitis (CHT) in comparison to 24 patients with acute peritonsillar abscess (PTA) was performed. Blood samples for clinical routine hematological and serological parameters were assessed prior to surgery (T-1) and five days (T5) after tonsillectomy. Outcome 6 months later (T180) was documented using the Glasgow Benefit Inventory (GBI) and the Specific Benefits from Tonsillectomy Inventory (SBTI). Correlation analyses between CHT and PTA group as well as between the different time points within each group concerning the serological parameters and the outcome parameters were performed.

Results: At T-1, patients in the CHT group presented with significantly higher lymphocytes counts (relative and absolute), basophils (relative and absolute) and eosinophils but less white-cells, monocytes, neutrophils (absolute and relative), alpha-1, alpha-2, beta globulins, immunoglobulin and lower C-reactive protein and procalcitonin values than patients in the PTA group (all p < 0.05, respectively). Within each group, different significant changes of the serum parameters (often in opposite direction) were observed between T-1 and T5. SBTI scores at T-1 were significantly lower in the CHT group. In contrast, most GBI scores at T180 were significantly higher in the CHT group. Between T-1 and T180 the SBTI scores improved in three quarters of the CHT patients but only in three fifths of the PTA patients. Higher eosinophil counts and immunoglobulin E levels at T-1 predicted higher GBI scores at T180 in the CHT group.

Conclusions: This pilot study showed a specific serological pattern for patients with chronic tonsillitis with a specific pattern of changes after tonsillectomy. But there is no established role for biomarkers currently used in clinical practice to predict the outcome of tonsillectomy for chronic tonsillitis.

背景:本研究的目的是探讨预测慢性扁桃体炎扁桃体切除术结果的血清学生物标志物。方法:对某大学耳鼻喉科24例成人慢性扁桃体炎(CHT)患者与24例急性扁桃体周围脓肿(PTA)患者进行病例分析。术前(T-1)和扁桃体切除术后5天(T5)评估临床常规血液学和血清学参数的血液样本。6个月后(T180)的结果使用格拉斯哥获益量表(GBI)和扁桃体切除术特定获益量表(SBTI)进行记录。分析CHT组与PTA组之间以及各组不同时间点血清学参数和转归参数的相关性。结果:在T-1时,CHT组患者淋巴细胞计数(相对和绝对)、嗜碱性粒细胞(相对和绝对)和嗜酸性粒细胞明显高于PTA组,白细胞、单核细胞、中性粒细胞(绝对和相对)、α -1、α -2、β球蛋白、免疫球蛋白明显低于PTA组,c反应蛋白和降钙素原值明显低于PTA组(均p)。这项初步研究显示,慢性扁桃体炎患者在扁桃体切除术后具有特定的血清学模式。但是目前在临床实践中还没有确定的生物标志物用于预测慢性扁桃体炎扁桃体切除术的结果。
{"title":"Clinical significance and diagnostic usefulness of serologic markers for improvement of outcome of tonsillectomy in adults with chronic tonsillitis.","authors":"Silvia Bohne,&nbsp;Robert Siggel,&nbsp;Svea Sachse,&nbsp;Michael Kiehntopf,&nbsp;Michael Bauer,&nbsp;Eberhard Straube,&nbsp;Orlando Guntinas-Lichius","doi":"10.1186/1477-5751-12-11","DOIUrl":"https://doi.org/10.1186/1477-5751-12-11","url":null,"abstract":"<p><strong>Background: </strong>The aim of the present study was to explore serological biomarkers which predict the outcome of tonsillectomy for chronic tonsillitis.</p><p><strong>Methods: </strong>A case study in a University ENT department of 24 adult patients with chronic tonsillitis (CHT) in comparison to 24 patients with acute peritonsillar abscess (PTA) was performed. Blood samples for clinical routine hematological and serological parameters were assessed prior to surgery (T-1) and five days (T5) after tonsillectomy. Outcome 6 months later (T180) was documented using the Glasgow Benefit Inventory (GBI) and the Specific Benefits from Tonsillectomy Inventory (SBTI). Correlation analyses between CHT and PTA group as well as between the different time points within each group concerning the serological parameters and the outcome parameters were performed.</p><p><strong>Results: </strong>At T-1, patients in the CHT group presented with significantly higher lymphocytes counts (relative and absolute), basophils (relative and absolute) and eosinophils but less white-cells, monocytes, neutrophils (absolute and relative), alpha-1, alpha-2, beta globulins, immunoglobulin and lower C-reactive protein and procalcitonin values than patients in the PTA group (all p < 0.05, respectively). Within each group, different significant changes of the serum parameters (often in opposite direction) were observed between T-1 and T5. SBTI scores at T-1 were significantly lower in the CHT group. In contrast, most GBI scores at T180 were significantly higher in the CHT group. Between T-1 and T180 the SBTI scores improved in three quarters of the CHT patients but only in three fifths of the PTA patients. Higher eosinophil counts and immunoglobulin E levels at T-1 predicted higher GBI scores at T180 in the CHT group.</p><p><strong>Conclusions: </strong>This pilot study showed a specific serological pattern for patients with chronic tonsillitis with a specific pattern of changes after tonsillectomy. But there is no established role for biomarkers currently used in clinical practice to predict the outcome of tonsillectomy for chronic tonsillitis.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31547595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. 一项评估草过敏免疫治疗片剂在伴有或不伴有结膜炎、伴或不伴有哮喘的草花粉性过敏性鼻炎患者中的疗效和安全性的三期试验。
Pub Date : 2013-06-01 DOI: 10.1186/1477-5751-12-10
Kevin Murphy, Sandra Gawchik, David Bernstein, Jens Andersen, Martin Rud Pedersen

Background: Design and execution of immunotherapy trials for seasonal allergies may be complicated by numerous factors including variable allergy testing methods, pollen levels, and timing and intensity of other seasonal allergens. We evaluated grass allergy immunotherapy tablet (AIT) treatment in North American adults with grass pollen-induced allergic rhinitis with or without conjunctivitis (AR/C), with/without asthma.

Methods: Subjects age 18-65 with clinical history of grass pollen-induced AR/C, with/without asthma were randomized 1:1 to once-daily 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, containing approximately 15 μg of Phl p 5) or placebo. The AR/C symptom and medication scores were recorded daily. The primary end point was the average AR/C daily symptom score (DSS) during the entire grass pollen season (GPS). Ranked key secondary end points were Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, daily medication score (DMS), and percentage of well days, all over entire GPS. Safety was monitored through adverse event reporting.

Results: Efficacy analysis included 289 subjects. Over the entire GPS, mean DSS was 6% lower with AIT versus placebo (5.69 vs. 6.06), but this difference was not statistically significant (p = 0.3475) despite significantly higher immunological response in the grass AIT group. No significant between-group differences were seen for key secondary end points. In general, DSS was high before GPS began and no clear relationship between DSS and grass pollen counts was seen during GPS. In post hoc analysis of subjects with pre-seasonal DSS ≤3, mean DSS and DMS were both significantly lower with grass AIT versus placebo (27%; p = 0.0327 and 68%; p = 0.0060, respectively). In this subgroup a relationship between DSS and grass pollen counts was observed. Grass AIT was generally well tolerated, with no events of anaphylactic shock or respiratory compromise.

Conclusions: In this trial, 2800 BAU grass AIT did not demonstrate significant symptom improvement versus placebo. Lack of relationship between pollen count and symptom score in the study population, and post hoc findings among subjects with low pre-seasonal symptoms, suggest that the symptoms reported in this study were not primarily reflective of the effects of grass pollen exposure.

Trial registration: NCT00421655.

背景:季节性过敏的免疫治疗试验的设计和实施可能会受到多种因素的影响,包括不同的过敏试验方法、花粉水平、其他季节性过敏原的时间和强度。我们评估了草过敏免疫治疗片(AIT)在北美成人草花粉诱导的过敏性鼻炎伴或不伴结膜炎(AR/C),伴/不伴哮喘的治疗。方法:年龄18-65岁,有草花粉诱导的AR/C临床病史,伴有/不伴有哮喘的受试者按1:1的比例随机分为每日一次2800 BAU的Timothy grass AIT(口服冻干液,phum pratense, 75000 SQ-T,含php5约15 μg)或安慰剂。每日记录AR/C症状和用药评分。主要终点是整个草花粉季节(GPS)的平均AR/C每日症状评分(DSS)。排名的关键次要终点是鼻结膜炎生活质量问卷(RQLQ)评分、每日用药评分(DMS)和健康天数百分比,全部在整个GPS中。通过不良事件报告监测安全性。结果:疗效分析纳入289例受试者。在整个GPS中,AIT组的平均DSS比安慰剂组低6%(5.69比6.06),但尽管草AIT组的免疫反应明显更高,但这种差异无统计学意义(p = 0.3475)。关键次要终点组间无显著差异。总体而言,DSS在GPS开始前较高,GPS开始时DSS与草花粉数量之间没有明显的关系。在季节前DSS≤3的受试者的事后分析中,草皮AIT的平均DSS和DMS均显著低于安慰剂(27%;P = 0.0327和68%;P = 0.0060)。在这个亚群中,DSS与草花粉数量之间存在相关性。Grass AIT一般耐受良好,无过敏性休克或呼吸损害事件。结论:在这项试验中,与安慰剂相比,2800 BAU grass AIT没有表现出显著的症状改善。在研究人群中,花粉计数和症状评分之间缺乏相关性,并且在季节性前症状较低的受试者中发现了一些特殊的发现,这表明本研究中报告的症状并不主要反映草花粉暴露的影响。试验注册:NCT00421655。
{"title":"A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.","authors":"Kevin Murphy,&nbsp;Sandra Gawchik,&nbsp;David Bernstein,&nbsp;Jens Andersen,&nbsp;Martin Rud Pedersen","doi":"10.1186/1477-5751-12-10","DOIUrl":"https://doi.org/10.1186/1477-5751-12-10","url":null,"abstract":"<p><strong>Background: </strong>Design and execution of immunotherapy trials for seasonal allergies may be complicated by numerous factors including variable allergy testing methods, pollen levels, and timing and intensity of other seasonal allergens. We evaluated grass allergy immunotherapy tablet (AIT) treatment in North American adults with grass pollen-induced allergic rhinitis with or without conjunctivitis (AR/C), with/without asthma.</p><p><strong>Methods: </strong>Subjects age 18-65 with clinical history of grass pollen-induced AR/C, with/without asthma were randomized 1:1 to once-daily 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, containing approximately 15 μg of Phl p 5) or placebo. The AR/C symptom and medication scores were recorded daily. The primary end point was the average AR/C daily symptom score (DSS) during the entire grass pollen season (GPS). Ranked key secondary end points were Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, daily medication score (DMS), and percentage of well days, all over entire GPS. Safety was monitored through adverse event reporting.</p><p><strong>Results: </strong>Efficacy analysis included 289 subjects. Over the entire GPS, mean DSS was 6% lower with AIT versus placebo (5.69 vs. 6.06), but this difference was not statistically significant (p = 0.3475) despite significantly higher immunological response in the grass AIT group. No significant between-group differences were seen for key secondary end points. In general, DSS was high before GPS began and no clear relationship between DSS and grass pollen counts was seen during GPS. In post hoc analysis of subjects with pre-seasonal DSS ≤3, mean DSS and DMS were both significantly lower with grass AIT versus placebo (27%; p = 0.0327 and 68%; p = 0.0060, respectively). In this subgroup a relationship between DSS and grass pollen counts was observed. Grass AIT was generally well tolerated, with no events of anaphylactic shock or respiratory compromise.</p><p><strong>Conclusions: </strong>In this trial, 2800 BAU grass AIT did not demonstrate significant symptom improvement versus placebo. Lack of relationship between pollen count and symptom score in the study population, and post hoc findings among subjects with low pre-seasonal symptoms, suggest that the symptoms reported in this study were not primarily reflective of the effects of grass pollen exposure.</p><p><strong>Trial registration: </strong>NCT00421655.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31471991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
Effects of a commercial product containing guaraná on psychological well-being, anxiety and mood: a single-blind, placebo-controlled study in healthy subjects. 含有瓜拉纳<e:1>的商业产品对心理健康、焦虑和情绪的影响:一项健康受试者的单盲、安慰剂对照研究
Pub Date : 2013-05-25 DOI: 10.1186/1477-5751-12-9
Gianluca Ivan Silvestrini, Franca Marino, Marco Cosentino

Background: Guaranà (Paulinia cupana) seed extracts are increasingly popular worldwide for their stimulant, cognitive and behavioral effects. To assess the effects on psychological well-being, anxiety and mood of a commercially available guaranà preparation taken regularly over several days according to the labelled dosages and instructions, 27 healthy volunteers were enrolled in a prospective, randomized, single-blind, placebo-controlled, crossover study.

Results: Guaranà 350 mg × 3 daily just after breakfast or placebo were given for 5 consecutive days. Assessment was performed one day after the last intake and included the psychological well-being (PWB) scales, the self-rating anxiety state scale (SAS), and the Bond-Lader mood scales. There were no significant differences between guaranà and placebo in any of the 6 areas of PWB, in SAS, as well as in any of the 16 mood scales.

Conclusions: In healthy subjects a 5-day treatment with a commercial preparation of guaranà used according to labelled instructions provided no evidence for any major effects on psychological well-being, anxiety and mood. Considering the increasing popularity of guaranà-containing products sold as dietary supplements for fitness purposes, controlled studies are strongly warranted to assess their benefits in comparison to the labelled claims.

瓜拉孔(Paulinia cupana)种子提取物因其兴奋,认知和行为作用而日益受到世界各地的欢迎。为了评估根据标签剂量和说明连续几天定期服用市售担保制剂对心理健康、焦虑和情绪的影响,27名健康志愿者参加了一项前瞻性、随机、单盲、安慰剂对照的交叉研究。结果:瓜拉康350mg × 3,每日早餐后服用或安慰剂,连续5天。最后一次服药后一天进行评估,包括心理健康(PWB)量表、焦虑状态自评量表(SAS)和Bond-Lader情绪量表。在PWB的6个领域中,在SAS中,以及在16个情绪量表中的任何一个方面,瓜拉康和安慰剂之间没有显着差异。结论:在健康受试者中,根据标签说明使用瓜拉康商业制剂进行5天治疗,没有证据表明对心理健康、焦虑和情绪有任何重大影响。考虑到guaranà-containing产品作为健身目的的膳食补充剂越来越受欢迎,对照研究是非常有必要的,以评估它们的好处与标签上的声明相比较。
{"title":"Effects of a commercial product containing guaraná on psychological well-being, anxiety and mood: a single-blind, placebo-controlled study in healthy subjects.","authors":"Gianluca Ivan Silvestrini,&nbsp;Franca Marino,&nbsp;Marco Cosentino","doi":"10.1186/1477-5751-12-9","DOIUrl":"https://doi.org/10.1186/1477-5751-12-9","url":null,"abstract":"<p><strong>Background: </strong>Guaranà (Paulinia cupana) seed extracts are increasingly popular worldwide for their stimulant, cognitive and behavioral effects. To assess the effects on psychological well-being, anxiety and mood of a commercially available guaranà preparation taken regularly over several days according to the labelled dosages and instructions, 27 healthy volunteers were enrolled in a prospective, randomized, single-blind, placebo-controlled, crossover study.</p><p><strong>Results: </strong>Guaranà 350 mg × 3 daily just after breakfast or placebo were given for 5 consecutive days. Assessment was performed one day after the last intake and included the psychological well-being (PWB) scales, the self-rating anxiety state scale (SAS), and the Bond-Lader mood scales. There were no significant differences between guaranà and placebo in any of the 6 areas of PWB, in SAS, as well as in any of the 16 mood scales.</p><p><strong>Conclusions: </strong>In healthy subjects a 5-day treatment with a commercial preparation of guaranà used according to labelled instructions provided no evidence for any major effects on psychological well-being, anxiety and mood. Considering the increasing popularity of guaranà-containing products sold as dietary supplements for fitness purposes, controlled studies are strongly warranted to assess their benefits in comparison to the labelled claims.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31455288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Neuropathogenic Escherichia coli K1 does not exhibit proteolytic activities to exert its pathogenicity. 神经致病性大肠杆菌K1不表现出蛋白水解活性来发挥其致病性。
Pub Date : 2013-05-01 DOI: 10.1186/1477-5751-12-8
Junaid Iqbal, Mehak Rajani, Ruqaiyyah Siddiqui, Naveed Ahmed Khan

Background: Proteases are well-known virulence factors that promote survival, pathogenesis and immune evasion of many pathogens. Several lines of evidence suggest that the blood-brain barrier permeability is a prerequisite in microbial invasion of the central nervous system. Because proteases are frequently associated with vascular permeability by targeting junctional proteins, here it is hypothesized that neuropathogenic Escherichia coli K1 exhibit proteolytic activities to exert its pathogenicity.

Methods: Zymographic assays were performed using collagen and gelatin as substrates. The lysates of whole E. coli K1 strain E44, or E. coli K-12 strain HB101 were tested for proteolytic activities. The conditioned media were prepared by incubating bacteria in RPMI-1640 in the presence or absence of serum. The cell-free supernatants were collected and tested for proteases in zymography as mentioned above. Additionally, proteolytic degradation of host immune factors was determined by co-incubating conditioned media with albumin/immunoglobulins using protease assays.

Results: When collagen or gelatin were used as substrates in zymographic assays, neither whole bacteria nor conditioned media exhibited proteolytic activities. The conditioned media of neuropathogenic E. coli K1 strain E44, or E. coli K-12 strain HB101 did not affect degradation of albumin and immunoglobulins using protease assays.

Conclusions: Neither zymographic assays nor protease assays detected proteolytic activities in either the whole bacteria or conditioned media of E. coli K1 strain E44 and E. coli K-12 strain HB101. These findings suggest that host cell monolayer disruptions and immune evasion strategies are likely independent of proteolytic activities of neuropathogenic E. coli K1.

背景:蛋白酶是众所周知的毒力因子,促进许多病原体的生存、发病和免疫逃避。几条线索的证据表明,血脑屏障的渗透性是微生物入侵中枢神经系统的先决条件。由于蛋白酶经常通过靶向连接蛋白与血管通透性相关,因此这里假设神经致病性大肠杆菌K1表现出蛋白水解活性以发挥其致病性。方法:以胶原蛋白和明胶为底物进行酶谱分析。对大肠杆菌K1菌株E44和大肠杆菌K-12菌株HB101的裂解物进行蛋白水解活性测定。在RPMI-1640中培养细菌,在血清存在或不存在的情况下制备条件培养基。收集无细胞上清液,按上述方法进行酶谱法检测蛋白酶。此外,宿主免疫因子的蛋白水解降解是通过用蛋白酶测定白蛋白/免疫球蛋白共孵育条件培养基来确定的。结果:当胶原蛋白或明胶作为底物进行酶谱分析时,整个细菌和条件培养基都没有表现出蛋白水解活性。通过蛋白酶测定,神经致病性大肠杆菌K1菌株E44或大肠杆菌K-12菌株HB101的条件培养基不影响白蛋白和免疫球蛋白的降解。结论:酶谱法和蛋白酶法均未检测到大肠杆菌K1菌株E44和大肠杆菌K-12菌株HB101在全菌或条件培养基中的蛋白水解活性。这些发现表明,宿主细胞单层破坏和免疫逃避策略可能独立于神经致病性大肠杆菌K1的蛋白水解活性。
{"title":"Neuropathogenic Escherichia coli K1 does not exhibit proteolytic activities to exert its pathogenicity.","authors":"Junaid Iqbal,&nbsp;Mehak Rajani,&nbsp;Ruqaiyyah Siddiqui,&nbsp;Naveed Ahmed Khan","doi":"10.1186/1477-5751-12-8","DOIUrl":"https://doi.org/10.1186/1477-5751-12-8","url":null,"abstract":"<p><strong>Background: </strong>Proteases are well-known virulence factors that promote survival, pathogenesis and immune evasion of many pathogens. Several lines of evidence suggest that the blood-brain barrier permeability is a prerequisite in microbial invasion of the central nervous system. Because proteases are frequently associated with vascular permeability by targeting junctional proteins, here it is hypothesized that neuropathogenic Escherichia coli K1 exhibit proteolytic activities to exert its pathogenicity.</p><p><strong>Methods: </strong>Zymographic assays were performed using collagen and gelatin as substrates. The lysates of whole E. coli K1 strain E44, or E. coli K-12 strain HB101 were tested for proteolytic activities. The conditioned media were prepared by incubating bacteria in RPMI-1640 in the presence or absence of serum. The cell-free supernatants were collected and tested for proteases in zymography as mentioned above. Additionally, proteolytic degradation of host immune factors was determined by co-incubating conditioned media with albumin/immunoglobulins using protease assays.</p><p><strong>Results: </strong>When collagen or gelatin were used as substrates in zymographic assays, neither whole bacteria nor conditioned media exhibited proteolytic activities. The conditioned media of neuropathogenic E. coli K1 strain E44, or E. coli K-12 strain HB101 did not affect degradation of albumin and immunoglobulins using protease assays.</p><p><strong>Conclusions: </strong>Neither zymographic assays nor protease assays detected proteolytic activities in either the whole bacteria or conditioned media of E. coli K1 strain E44 and E. coli K-12 strain HB101. These findings suggest that host cell monolayer disruptions and immune evasion strategies are likely independent of proteolytic activities of neuropathogenic E. coli K1.</p>","PeriodicalId":73849,"journal":{"name":"Journal of negative results in biomedicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1477-5751-12-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31491593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Journal of negative results in biomedicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1